scPharmaceuticals (SCPH) Prices 5.78M Share Common Offering at $8.65/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/11/2026
- Wall St futures recover as oil slides ahead of inflation test
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but on track for 8% weekly gain on supply concerns; US diesel hits record high
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- White House copper tariff plan stalls amid affordability concerns, sources say
- Micron's Taiwan workers to get rewards worth up to 68 months of pay
- Crude Inventory 0.4M Barrels Last Week - EIA
- Vertiv shares drop on acquisition skepticism, AI pullback
- S&P 500, Dow futures attempt recovery ahead of inflation report
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
After-Hours Movers 05/20: (ACB) (SCVL) (EXPE) Higher; (SCPH) (GLPG) (FLXN) Lower (more...)
May 20, 2020 6:07 PM EDTToday's After-Hours Movers
Aurora Cannabis Inc. (NYSE: ACB) 28.6% HIGHER; entered into an agreement pursuant to which Aurora will acquire all of the issued and outstanding membership interests of Reliva. Under the terms of the agreement, members of Reliva will receive approximately US$40 million of Aurora common shares. The transaction also includes a potential earn-out of up to a maximum of US$45 million payable in Aurora shares, cash or a combination thereof, over the next two years contingent upon Reliva achieving certain financial targets.
scPharmaceuticals Inc. (Nasdaq:... More
scPharmaceuticals (SCPH) Announces Proposed Underwritten Public Offering of Common Stock
May 20, 2020 4:02 PM EDTscPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that it has commenced an underwritten public offering of... More
